Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 118 entries
Sorted by: Best Match Show Resources per page
What should clinicians know about the renal effect and the mechanism of action of levosimendan?.

Expert opinion on drug safety

Honore PM, Redant S, Moorthamers S, Preseau T, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, Boer W, De Bels D.
PMID: 34612116
Expert Opin Drug Saf. 2021 Dec;20(12):1459-1461. doi: 10.1080/14740338.2021.1986483. Epub 2021 Oct 18.

No abstract available.

Cite
Honore PM, Redant S, Moorthamers S, et al. What should clinicians know about the renal effect and the mechanism of action of levosimendan?. Expert Opin Drug Saf. 2021;20(12):1459-1461doi: 10.1080/14740338.2021.1986483.
Honore, P. M., Redant, S., Moorthamers, S., Preseau, T., Kaefer, K., Barreto Gutierrez, L., Attou, R., Gallerani, A., Boer, W., & De Bels, D. (2021). What should clinicians know about the renal effect and the mechanism of action of levosimendan?. Expert opinion on drug safety, 20(12), 1459-1461. https://doi.org/10.1080/14740338.2021.1986483
Honore, Patrick M, et al. "What should clinicians know about the renal effect and the mechanism of action of levosimendan?." Expert opinion on drug safety vol. 20,12 (2021): 1459-1461. doi: https://doi.org/10.1080/14740338.2021.1986483
Honore PM, Redant S, Moorthamers S, Preseau T, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, Boer W, De Bels D. What should clinicians know about the renal effect and the mechanism of action of levosimendan?. Expert Opin Drug Saf. 2021 Dec;20(12):1459-1461. doi: 10.1080/14740338.2021.1986483. Epub 2021 Oct 18. PMID: 34612116.
Copy Download .nbib Format: NLM
In Septic ICU Patients, Presepsin is Predictor of AKI, ARDS, and DIC: Beware of Some Potential Confounding Factors!.

Shock (Augusta, Ga.)

Honore PM, Redant S, Preseau T, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D.
PMID: 33927138
Shock. 2021 Dec 01;56(6):1092. doi: 10.1097/SHK.0000000000001802.

No abstract available.

Cite
Honore PM, Redant S, Preseau T, et al. In Septic ICU Patients, Presepsin is Predictor of AKI, ARDS, and DIC: Beware of Some Potential Confounding Factors!. Shock. 2021;56(6):1092doi: 10.1097/SHK.0000000000001802.
Honore, P. M., Redant, S., Preseau, T., Kaefer, K., Barreto Gutierrez, L., Attou, R., Gallerani, A., & De Bels, D. (2021). In Septic ICU Patients, Presepsin is Predictor of AKI, ARDS, and DIC: Beware of Some Potential Confounding Factors!. Shock (Augusta, Ga.), 56(6), 1092. https://doi.org/10.1097/SHK.0000000000001802
Honore, Patrick M, et al. "In Septic ICU Patients, Presepsin is Predictor of AKI, ARDS, and DIC: Beware of Some Potential Confounding Factors!." Shock (Augusta, Ga.) vol. 56,6 (2021): 1092. doi: https://doi.org/10.1097/SHK.0000000000001802
Honore PM, Redant S, Preseau T, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D. In Septic ICU Patients, Presepsin is Predictor of AKI, ARDS, and DIC: Beware of Some Potential Confounding Factors!. Shock. 2021 Dec 01;56(6):1092. doi: 10.1097/SHK.0000000000001802. PMID: 33927138.
Copy Download .nbib Format: NLM
National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research.

Intensive care medicine experimental

Mendelson AA, Lansdell C, Fox-Robichaud AE, Liaw P, Arora J, Cailhier JF, Cepinskas G, Charbonney E, Dos Santos C, Dwivedi D, Ellis CG, Fergusson D, Fiest K, Gill SE, Hendrick K, Hunniford VT, Kowalewska PM, Krewulak K, Lehmann C, Macala K, Marshall JC, Mawdsley L, McDonald B, McDonald E, Medeiros SK, Muniz VS, Osuchowski M, Presseau J, Sharma N, Sohrabipour S, Sunohara-Neilson J, Vázquez-Grande G, Veldhuizen RAW, Welsh D, Winston BW, Zarychanski R, Zhang H, Zhou J, Lalu MM.
PMID: 33738642
Intensive Care Med Exp. 2021 Mar 19;9(1):14. doi: 10.1186/s40635-020-00366-4.

Despite decades of preclinical research, no experimentally derived therapies for sepsis have been successfully adopted into routine clinical practice. Factors that contribute to this crisis of translation include poor representation by preclinical models of the complex human condition of...

Cite
Mendelson AA, Lansdell C, Fox-Robichaud AE, et al. National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research. Intensive Care Med Exp. 2021;9(1):14doi: 10.1186/s40635-020-00366-4.
Mendelson, A. A., Lansdell, C., Fox-Robichaud, A. E., Liaw, P., Arora, J., Cailhier, J. F., Cepinskas, G., Charbonney, E., Dos Santos, C., Dwivedi, D., Ellis, C. G., Fergusson, D., Fiest, K., Gill, S. E., Hendrick, K., Hunniford, V. T., Kowalewska, P. M., Krewulak, K., Lehmann, C., Macala, K., Marshall, J. C., Mawdsley, L., McDonald, B., McDonald, E., Medeiros, S. K., Muniz, V. S., Osuchowski, M., Presseau, J., Sharma, N., Sohrabipour, S., Sunohara-Neilson, J., Vázquez-Grande, G., Veldhuizen, R. A. W., Welsh, D., Winston, B. W., Zarychanski, R., Zhang, H., Zhou, J., Lalu, M. M. (2021). National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research. Intensive care medicine experimental, 9(1), 14. https://doi.org/10.1186/s40635-020-00366-4
Mendelson, Asher A, et al. "National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research." Intensive care medicine experimental vol. 9,1 (2021): 14. doi: https://doi.org/10.1186/s40635-020-00366-4
Mendelson AA, Lansdell C, Fox-Robichaud AE, Liaw P, Arora J, Cailhier JF, Cepinskas G, Charbonney E, Dos Santos C, Dwivedi D, Ellis CG, Fergusson D, Fiest K, Gill SE, Hendrick K, Hunniford VT, Kowalewska PM, Krewulak K, Lehmann C, Macala K, Marshall JC, Mawdsley L, McDonald B, McDonald E, Medeiros SK, Muniz VS, Osuchowski M, Presseau J, Sharma N, Sohrabipour S, Sunohara-Neilson J, Vázquez-Grande G, Veldhuizen RAW, Welsh D, Winston BW, Zarychanski R, Zhang H, Zhou J, Lalu MM. National Preclinical Sepsis Platform: developing a framework for accelerating innovation in Canadian sepsis research. Intensive Care Med Exp. 2021 Mar 19;9(1):14. doi: 10.1186/s40635-020-00366-4. PMID: 33738642; PMCID: PMC7973346.
Copy Download .nbib Format: NLM
Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!.

Journal of critical care

Honore PM, Redant S, Preseau T, Moorthamers S, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D.
PMID: 34690036
J Crit Care. 2022 Feb;67:219-220. doi: 10.1016/j.jcrc.2021.10.005. Epub 2021 Oct 22.

No abstract available.

Cite
Honore PM, Redant S, Preseau T, et al. Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!. J Crit Care. 2021;67:219-220doi: 10.1016/j.jcrc.2021.10.005.
Honore, P. M., Redant, S., Preseau, T., Moorthamers, S., Kaefer, K., Barreto Gutierrez, L., Attou, R., Gallerani, A., & De Bels, D. (2022). Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!. Journal of critical care, 67219-220. https://doi.org/10.1016/j.jcrc.2021.10.005
Honore, Patrick M, et al. "Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!." Journal of critical care vol. 67 (2022): 219-220. doi: https://doi.org/10.1016/j.jcrc.2021.10.005
Honore PM, Redant S, Preseau T, Moorthamers S, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D. Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!. J Crit Care. 2022 Feb;67:219-220. doi: 10.1016/j.jcrc.2021.10.005. Epub 2021 Oct 22. PMID: 34690036; PMCID: PMC8531039.
Copy Download .nbib Format: NLM
Smoking and Cannabis Use among Childhood Cancer Survivors: Results of the French Childhood Cancer Survivor Study.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Bougas N, Fresneau B, Pinto S, Mayet A, Marchi J, Pein F, Mansouri I, Journy NMY, Jackson A, Souchard V, Demoor-Goldschmidt C, Vu-Bezin G, Rubino C, Oberlin O, Haddy N, de Vathaire F, Allodji RS, Dumas A.
PMID: 34321283
Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1965-1973. doi: 10.1158/1055-9965.EPI-21-0193. Epub 2021 Jul 28.

BACKGROUND: Unhealthy behaviors among childhood cancer survivors increase the risks for cancer treatment adverse effects. We aimed to assess tobacco and cannabis use prevalence in this population and to identify factors associated with these consumptions.METHODS: This study involved 2,887...

Cite
Bougas N, Fresneau B, Pinto S, et al. Smoking and Cannabis Use among Childhood Cancer Survivors: Results of the French Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2021;30(10):1965-1973doi: 10.1158/1055-9965.EPI-21-0193.
Bougas, N., Fresneau, B., Pinto, S., Mayet, A., Marchi, J., Pein, F., Mansouri, I., Journy, N. M. Y., Jackson, A., Souchard, V., Demoor-Goldschmidt, C., Vu-Bezin, G., Rubino, C., Oberlin, O., Haddy, N., de Vathaire, F., Allodji, R. S., & Dumas, A. (2021). Smoking and Cannabis Use among Childhood Cancer Survivors: Results of the French Childhood Cancer Survivor Study. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(10), 1965-1973. https://doi.org/10.1158/1055-9965.EPI-21-0193
Bougas, Nicolas, et al. "Smoking and Cannabis Use among Childhood Cancer Survivors: Results of the French Childhood Cancer Survivor Study." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 30,10 (2021): 1965-1973. doi: https://doi.org/10.1158/1055-9965.EPI-21-0193
Bougas N, Fresneau B, Pinto S, Mayet A, Marchi J, Pein F, Mansouri I, Journy NMY, Jackson A, Souchard V, Demoor-Goldschmidt C, Vu-Bezin G, Rubino C, Oberlin O, Haddy N, de Vathaire F, Allodji RS, Dumas A. Smoking and Cannabis Use among Childhood Cancer Survivors: Results of the French Childhood Cancer Survivor Study. Cancer Epidemiol Biomarkers Prev. 2021 Oct;30(10):1965-1973. doi: 10.1158/1055-9965.EPI-21-0193. Epub 2021 Jul 28. PMID: 34321283.
Copy Download .nbib Format: NLM
MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!.

Journal of critical care

Honore PM, Redant S, Moorthamers S, Preseau T, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D.
PMID: 34690034
J Crit Care. 2021 Oct 21; doi: 10.1016/j.jcrc.2021.10.007. Epub 2021 Oct 21.

No abstract available.

Cite
Honore PM, Redant S, Moorthamers S, et al. MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!. J Crit Care. 2021;doi: 10.1016/j.jcrc.2021.10.007.
Honore, P. M., Redant, S., Moorthamers, S., Preseau, T., Kaefer, K., Barreto Gutierrez, L., Attou, R., Gallerani, A., & De Bels, D. (2021). MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!. Journal of critical care, . https://doi.org/10.1016/j.jcrc.2021.10.007
Honore, Patrick M, et al. "MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!." Journal of critical care vol. (2021). doi: https://doi.org/10.1016/j.jcrc.2021.10.007
Honore PM, Redant S, Moorthamers S, Preseau T, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D. MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!. J Crit Care. 2021 Oct 21; doi: 10.1016/j.jcrc.2021.10.007. Epub 2021 Oct 21. PMID: 34690034; PMCID: PMC8530787.
Copy Download .nbib Format: NLM
Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics.

Genome medicine

Guilhamon P, Butcher LM, Presneau N, Wilson GA, Feber A, Paul DS, Schütte M, Haybaeck J, Keilholz U, Hoffman J, Ross MT, Flanagan AM, Beck S.
PMID: 25587359
Genome Med. 2014 Dec 12;6(12):116. doi: 10.1186/s13073-014-0116-0. eCollection 2014.

BACKGROUND: The use of tumour xenografts is a well-established research tool in cancer genomics but has not yet been comprehensively evaluated for cancer epigenomics.METHODS: In this study, we assessed the suitability of patient-derived tumour xenografts (PDXs) for methylome analysis...

Cite
Guilhamon P, Butcher LM, Presneau N, et al. Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. Genome Med. 2014;6(12):116doi: 10.1186/s13073-014-0116-0.
Guilhamon, P., Butcher, L. M., Presneau, N., Wilson, G. A., Feber, A., Paul, D. S., Schütte, M., Haybaeck, J., Keilholz, U., Hoffman, J., Ross, M. T., Flanagan, A. M., & Beck, S. (2014). Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. Genome medicine, 6(12), 116. https://doi.org/10.1186/s13073-014-0116-0
Guilhamon, Paul, et al. "Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics." Genome medicine vol. 6,12 (2014): 116. doi: https://doi.org/10.1186/s13073-014-0116-0
Guilhamon P, Butcher LM, Presneau N, Wilson GA, Feber A, Paul DS, Schütte M, Haybaeck J, Keilholz U, Hoffman J, Ross MT, Flanagan AM, Beck S. Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics. Genome Med. 2014 Dec 12;6(12):116. doi: 10.1186/s13073-014-0116-0. eCollection 2014. PMID: 25587359; PMCID: PMC4292812.
Copy Download .nbib Format: NLM
Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!.

Journal of critical care

Honore PM, Redant S, Preseau T, Moorthamers S, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D.
PMID: 34690036
J Crit Care. 2022 Feb;67:219-220. doi: 10.1016/j.jcrc.2021.10.005. Epub 2021 Oct 22.

No abstract available.

Cite
Honore PM, Redant S, Preseau T, et al. Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!. J Crit Care. 2021;67:219-220doi: 10.1016/j.jcrc.2021.10.005.
Honore, P. M., Redant, S., Preseau, T., Moorthamers, S., Kaefer, K., Barreto Gutierrez, L., Attou, R., Gallerani, A., & De Bels, D. (2022). Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!. Journal of critical care, 67219-220. https://doi.org/10.1016/j.jcrc.2021.10.005
Honore, Patrick M, et al. "Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!." Journal of critical care vol. 67 (2022): 219-220. doi: https://doi.org/10.1016/j.jcrc.2021.10.005
Honore PM, Redant S, Preseau T, Moorthamers S, Kaefer K, Barreto Gutierrez L, Attou R, Gallerani A, De Bels D. Study conclude that routinely monitoring of sputum viral load in severe COVID-19 patients may be beneficial for development of infection control guidelines and prediction of prognosis: We are not sure!. J Crit Care. 2022 Feb;67:219-220. doi: 10.1016/j.jcrc.2021.10.005. Epub 2021 Oct 22. PMID: 34690036; PMCID: PMC8531039.
Copy Download .nbib Format: NLM
Gender-based violence and suicidal ideation among Indian women from slums: An examination of direct and indirect effects of depression, anxiety, and PTSD symptoms.

Psychological trauma : theory, research, practice and policy

Patel AR, Prabhu S, Sciarrino NA, Presseau C, Smith NB, Rozek DC.
PMID: 33507794
Psychol Trauma. 2021 Jan 28; doi: 10.1037/tra0000998. Epub 2021 Jan 28.

OBJECTIVE: India accounts for 36.6% of suicide-related deaths among women worldwide. One social determinant of suicide in India is gender-based violence (GBV), and it disproportionately affects women from poorer socioeconomic classes. Although Indian women from slums are at high...

Cite
Patel AR, Prabhu S, Sciarrino NA, et al. Gender-based violence and suicidal ideation among Indian women from slums: An examination of direct and indirect effects of depression, anxiety, and PTSD symptoms. Psychol Trauma. 2021;doi: 10.1037/tra0000998.
Patel, A. R., Prabhu, S., Sciarrino, N. A., Presseau, C., Smith, N. B., & Rozek, D. C. (2021). Gender-based violence and suicidal ideation among Indian women from slums: An examination of direct and indirect effects of depression, anxiety, and PTSD symptoms. Psychological trauma : theory, research, practice and policy, . https://doi.org/10.1037/tra0000998
Patel, Anushka R, et al. "Gender-based violence and suicidal ideation among Indian women from slums: An examination of direct and indirect effects of depression, anxiety, and PTSD symptoms." Psychological trauma : theory, research, practice and policy vol. (2021). doi: https://doi.org/10.1037/tra0000998
Patel AR, Prabhu S, Sciarrino NA, Presseau C, Smith NB, Rozek DC. Gender-based violence and suicidal ideation among Indian women from slums: An examination of direct and indirect effects of depression, anxiety, and PTSD symptoms. Psychol Trauma. 2021 Jan 28; doi: 10.1037/tra0000998. Epub 2021 Jan 28. PMID: 33507794.
Copy Download .nbib Format: NLM
T-CaST: an implementation theory comparison and selection tool.

Implementation science : IS

Birken SA, Rohweder CL, Powell BJ, Shea CM, Scott J, Leeman J, Grewe ME, Alexis Kirk M, Damschroder L, Aldridge WA, Haines ER, Straus S, Presseau J.
PMID: 30466450
Implement Sci. 2018 Nov 22;13(1):143. doi: 10.1186/s13012-018-0836-4.

BACKGROUND: Theories, models, and frameworks (TMF) are foundational for generalizing implementation efforts and research findings. However, TMF and the criteria used to select them are not often described in published articles, perhaps due in part to the challenge of...

Cite
Birken SA, Rohweder CL, Powell BJ, et al. T-CaST: an implementation theory comparison and selection tool. Implement Sci. 2018;13(1):143doi: 10.1186/s13012-018-0836-4.
Birken, S. A., Rohweder, C. L., Powell, B. J., Shea, C. M., Scott, J., Leeman, J., Grewe, M. E., Alexis Kirk, M., Damschroder, L., Aldridge, W. A., Haines, E. R., Straus, S., & Presseau, J. (2018). T-CaST: an implementation theory comparison and selection tool. Implementation science : IS, 13(1), 143. https://doi.org/10.1186/s13012-018-0836-4
Birken, Sarah A, et al. "T-CaST: an implementation theory comparison and selection tool." Implementation science : IS vol. 13,1 (2018): 143. doi: https://doi.org/10.1186/s13012-018-0836-4
Birken SA, Rohweder CL, Powell BJ, Shea CM, Scott J, Leeman J, Grewe ME, Alexis Kirk M, Damschroder L, Aldridge WA, Haines ER, Straus S, Presseau J. T-CaST: an implementation theory comparison and selection tool. Implement Sci. 2018 Nov 22;13(1):143. doi: 10.1186/s13012-018-0836-4. PMID: 30466450; PMCID: PMC6251099.
Copy Download .nbib Format: NLM
Citrate: How to Get Started and What, When, and How to Monitor?.

Journal of translational internal medicine

Honore PM, De Bels D, Preseau T, Redant S, Spapen HD.
PMID: 30425947
J Transl Int Med. 2018 Oct 09;6(3):115-127. doi: 10.2478/jtim-2018-0026. eCollection 2018 Sep.

In most of the case, regional citrate anticoagulation is using diluted citrate around 1% depending on the types used in clinical practice. Diluted citrate is much more safer when compared to highly concentrated citrate around 4% or even more....

Cite
Honore PM, De Bels D, Preseau T, et al. Citrate: How to Get Started and What, When, and How to Monitor?. J Transl Int Med. 2018;6(3):115-127doi: 10.2478/jtim-2018-0026.
Honore, P. M., De Bels, D., Preseau, T., Redant, S., & Spapen, H. D. (2018). Citrate: How to Get Started and What, When, and How to Monitor?. Journal of translational internal medicine, 6(3), 115-127. https://doi.org/10.2478/jtim-2018-0026
Honore, Patrick M, et al. "Citrate: How to Get Started and What, When, and How to Monitor?." Journal of translational internal medicine vol. 6,3 (2018): 115-127. doi: https://doi.org/10.2478/jtim-2018-0026
Honore PM, De Bels D, Preseau T, Redant S, Spapen HD. Citrate: How to Get Started and What, When, and How to Monitor?. J Transl Int Med. 2018 Oct 09;6(3):115-127. doi: 10.2478/jtim-2018-0026. eCollection 2018 Sep. PMID: 30425947; PMCID: PMC6231307.
Copy Download .nbib Format: NLM
Anisodamine microcirulatory effects in septic shock: be aware of cardiac side effects.

Critical care (London, England)

Honore PM, Redant S, Preseau T, Cismas BV, Kaefer K, Barreto Gutierrez L, Anane S, Attou R, Gallerani A, De Bels D.
PMID: 34915896
Crit Care. 2021 Dec 16;25(1):433. doi: 10.1186/s13054-021-03854-5.

No abstract available.

Cite
Honore PM, Redant S, Preseau T, et al. Anisodamine microcirulatory effects in septic shock: be aware of cardiac side effects. Crit Care. 2021;25(1):433doi: 10.1186/s13054-021-03854-5.
Honore, P. M., Redant, S., Preseau, T., Cismas, B. V., Kaefer, K., Barreto Gutierrez, L., Anane, S., Attou, R., Gallerani, A., & De Bels, D. (2021). Anisodamine microcirulatory effects in septic shock: be aware of cardiac side effects. Critical care (London, England), 25(1), 433. https://doi.org/10.1186/s13054-021-03854-5
Honore, Patrick M, et al. "Anisodamine microcirulatory effects in septic shock: be aware of cardiac side effects." Critical care (London, England) vol. 25,1 (2021): 433. doi: https://doi.org/10.1186/s13054-021-03854-5
Honore PM, Redant S, Preseau T, Cismas BV, Kaefer K, Barreto Gutierrez L, Anane S, Attou R, Gallerani A, De Bels D. Anisodamine microcirulatory effects in septic shock: be aware of cardiac side effects. Crit Care. 2021 Dec 16;25(1):433. doi: 10.1186/s13054-021-03854-5. PMID: 34915896; PMCID: PMC8680269.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 118 entries